Chronic myeloid leukaemia (CML) mortality statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Deaths

Deaths from chronic myeloid leukaemia, 2015-2017, UK.

Proportion of all deaths

Percentage chronic myeloid leukaemia contributes to total cancer deaths, 2015-2017, UK

Age

Peak rate of chronic myeloid leukaemia deaths, 2015-2017, UK

 

 

Trend over time

Change in chronic myeloid leukaemia mortality rates since the early 1970s, UK

Chronic myeloid leukaemia accounted for less than 1% of all cancer deaths in the UK in 2017.[1-3]

In females in the UK, chronic myeloid leukaemia accounted for less than 1% of all female cancer deaths. In males in the UK it accounted for less than 1% of all male cancer deaths.

In 2017, 43% of chronic myeloid leukaemia deaths in the UK were in females and 57% were in males.

Chronic myeloid leukaemia mortality rates (European age-standardised (AS) rates Open a glossary item) are similar to the UK average in all the UK constituent countries.

Chronic Myeloid Leukaemia (C92.1), Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Deaths 91 8 4 0 103
Crude Rate 0.3 0.3 0.3 0.0 0.3
AS Rate 0.3 0.3 0.2 0.0 0.3
AS Rate - 95% LCL 0.2 0.1 0.0 N/A 0.2
AS Rate - 95% UCL 0.4 0.5 0.5 N/A 0.3
Male Deaths 125 5 3 3 136
Crude Rate 0.5 0.2 0.2 0.3 0.4
AS Rate 0.6 0.2 0.3 0.6 0.5
AS Rate - 95% LCL 0.5 0.0 0.0 0.0 0.4
AS Rate - 95% UCL 0.7 0.4 0.6 1.2 0.6
Persons Deaths 216 13 7 3 239
Crude Rate 0.4 0.2 0.2 0.2 0.4
AS Rate 0.4 0.3 0.2 0.2 0.4
AS Rate - 95% LCL 0.4 0.1 0.1 0.0 0.3
AS Rate - 95% UCL 0.5 0.4 0.4 0.4 0.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2015-2017, on average each year around two-thirds (67%) of deaths were in people aged 75 and over.[1-3] This largely reflects higher incidence and lower survival for chronic myeloid leukaemia in older people.

Age-specific mortality rates rise steeply from around age 60-64. The highest rates are in the 90+ age group for females and males. Mortality rates are similar between females and males in most age groups.

Chronic Myeloid Leukaemia (C92.1), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Population, UK, 2015-2017

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, October 2017. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp
  3. Data were provided by the Northern Ireland Cancer Registry on request, December 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2014-2016, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia European age-standardised (AS) Open a glossary item mortality rates for females and males combined decreased by 72% in the UK between 1971-1973 and 2015-2017.[1-3] The decrease was larger in females than in males.

For females, chronic myeloid leukaemia AS mortality rates in the UK decreased by 76% between 1971-1973 and 2015-2017. For males, chronic myeloid leukaemia AS mortality rates in the UK decreased by 71% between 1971-1973 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), chronic myeloid leukaemia AS mortality rates for females and males combined decreased by 19%. In females AS mortality rates decreased by 24%, and in males rates remained stable.

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates per 100,000 Population, UK, 1971-2017

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Chronic myeloid leukaemia mortality rates have decreased overall in all broad age groups in females and males combined in the UK since the early 1970s.[1-3] Rates in 0-24s have decreased by 90%, in 25-49s have decreased by 90%, in 50-59s have decreased by 93%, in 60-69s have decreased by 85%, in 70-79s have decreased by 72%, and in 80+s have decreased by 36%.

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates per 100,000 Population, By Age, UK, 1971-2017

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1971-2017, C92.1.

Last reviewed:

There is evidence for an association between chronic myeloid leukaemia (CML) mortality and deprivation for males in England, but there is no evidence for an association for females.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are 33% higher for males living in the most deprived areas compared with the least deprived, but for females the rates are similar for those living in the least and most deprived areas.[1]

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in CML mortality for males and females living in the most and least deprived areas in England has not changed in the period 2002-2011.[1] It has been estimated that there would have been around 15 fewer cancer deaths each year in England during 2007-2011 if all people experienced the same mortality rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2007-2011, ICD-10 C92.1

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.